Barbour Group - Grants
In the last five years we have received funding from:
- Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
- Radiomics analysis to improve outcomes for melanoma patients
(2023-2024) Cancer Australia, PdCCRs awarded to Dr Lauren Aoude
- Understanding predisposition to Oesophageal Adenocarcinoma through defects in DNA damage repair genes
(2023) Cure Cancer EMCR grant awarded to Dr Lauren Aoude
- Investigating the spatial and temporal tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma
(2022–2023) Cancer Australia, PdCCRs awarded to Dr Sandra Brosda
- Investigating tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma
(2022-2023) SERTA, Metro South research support scheme
- Improving outcomes for patients with melanoma brain metastases
(2020-2025) Civic Solutions: Community Skilling & Disability Support Service Inc
- Blood biomarkers to predict recurrence in BRAF-negative melanoma patients
(2020-2022) Queensland Health Clinical Advance Fellowship
(2020-2022) PA Research Foundation
- Role of Complement C3a and neutrophils in melanoma
(2020-2023) NHMRC Development Grant with Dr Barbara Rolfe (UQ)
- Statins as a potential therapeutic agent for Melanoma
(2018-2019) Australian Skin and Skin Cancer Research Centre (ASSC), Grant with Dr Jason Lee (QIMR Berghofer)
- Genomics and biological correlates of radiomics in melanoma
(2018-2019) Cure Cancer Australia PdCCRS awarded to Dr Lauren Aoude
- Improving oesophageal adenocarcinoma outcomes through understanding genomics and treatment toxicity: genomic analysis of the DOCTOR trial
(2018-2020) NHMRC Project Grant with Dr Nic Waddell (QIMR Berghofer)
- mFOLFIRINOX And STEreotactic body Radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG)
(2018-2023) MRFF clinical trial
- Tumour neo-antigen-specific immune responses in oesophageal cancer long term survivors: proof-of-concept for improved personalised therapeutic strategies
(2019-2020) Metro South Health Research Support Scheme Program Grant.
- Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer
(2019-2020) Avner Foundation with Dr John Hooper (Mater Research)
- ctDNA: Towards biomarkers of progression and prognosis in Oesophageal Cancer
(2018-2019) Roche Diagnostics